Clinical Trial Update: Study to Evaluate Safety, Tolerability, and Efficacy of GS-0976 in Adults With Nonalcoholic Steatohepatitis [Phase 2]

View source ↗

Summary

Phase 2 trial update for GS-0976 in adults with nonalcoholic steatohepatitis (NASH) completed with results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Steatohepatitis

Drugs mentioned

• GS-0976 (firsocostat)

Snippet

Sponsor: Gilead Sciences | Conditions: Nonalcoholic Steatohepatitis (NASH) | Phase 2 | Status: COMPLETED | Results posted: 2020-07-24